Omnio Raises €2.9M Seed for Plasminogen-Based Chronic Wound Therapy

Omnio Secures €2.9M Seed Round

Omnio AB, a Swedish biotechnology company based in Umeå, has raised €2.9 million in Seed funding. The round was announced on October 2, 2026.

What Omnio Does

Omnio is developing a plasminogen-based biologic therapy for hard-to-heal chronic wounds. The company's lead indication is diabetic foot ulcers.

Founded on research by Professor Tor Ny of Umeå University, Omnio is advancing a recombinant plasminogen drug candidate designed to restart the stalled wound-healing process. The platform has potential applications in venous leg ulcers, burns, and other chronic wound conditions.

Operations and Structure

Omnio's R&D operations are based in Umeå, Sweden. Clinical operations and quality functions are coordinated from Copenhagen and Barcelona.

Funding Details

• Round type: Seed
• Amount raised: €2.9 million
• Announced: October 2, 2026
• Lead investor: Not disclosed

Why This Matters for Acquisition Watchers

Omnio sits at the intersection of biologics and chronic wound care, a space with significant unmet need. Diabetic foot ulcers represent a costly and difficult-to-treat condition, and a plasminogen-based approach offers a differentiated mechanism of action.

The company's distributed operating model—R&D in Sweden, clinical and quality functions in Denmark and Spain—suggests a lean structure built for European clinical development.

With Seed funding in place, Omnio is positioned to advance its recombinant plasminogen candidate toward clinical milestones. For strategic acquirers in wound care, regenerative medicine, or biologics, Omnio represents an early-stage asset with a defined lead indication and a platform that could extend into adjacent chronic wound conditions.

Key Facts

• Company: Omnio AB
• Headquarters: Umeå, Sweden
• Focus: Plasminogen-based biologic therapy for chronic wounds
• Lead indication: Diabetic foot ulcers
• Founding research: Professor Tor Ny, Umeå University
• Stage: Seed
• Amount: €2.9 million
• Date: October 2, 2026